The financial report has entered the intensive disclosure period, and many pharmaceutical companies have released their 2018 transcripts

[industry trends of China Pharmaceutical network] April is the intensive disclosure period of annual report and first quarter report At present, many pharmaceutical companies, such as step pharmaceutical, Northeast Pharmaceutical, Puli pharmaceutical, HongRi pharmaceutical, Yifan pharmaceutical and Haichen pharmaceutical, have successively disclosed their performance in 2018, with their net profit increasing or decreasing Several pharmaceutical companies have also disclosed first quarter report Step pharmaceutical's net profit in 2018 increased by 15.31% year on year On April 2, step pharmaceutical released the announcement of 2018 performance express According to the express report, the company achieved 13.7 billion yuan of operating revenue, down 1.38% from the previous year; 2.3 billion yuan of operating profit, up 31.14% from the previous year; and 1.888 billion yuan of net profit attributable to shareholders of listed companies, up 15.31% from the previous year Step pharmaceutical explained that during the reporting period, the increase in government subsidies received by the company related to daily operations contributed to the growth of the company's operating profit and net profit for the year Northeast Pharmaceutical's net profit in 2018 increased by more than 60% year on year Northeast Pharmaceutical released its annual report for 2018 on the evening of April 2 During the reporting period, the company's operating revenue was 7.467 billion yuan, an increase of 31.54% year on year; the net profit attributable to the parent company was 195 million yuan, an increase of 64.04% year on year It is reported that in 2018, Northeast Pharmaceutical implemented the reform of mixed ownership, introduced strategic investors, and vigorously promoted the innovation of system and mechanism Especially since July 2018, Liaoning Fangda group, the controlling shareholder, has fundamentally managed a series of persistent diseases by importing mature, advanced and flexible management mode, business mode and efficiency mode, which has fully stimulated the power and vitality Puli pharmaceutical's net profit in 2018 increased by 84% year on year Puli pharmaceutical recently released its financial report in 2018, which showed that during the reporting period, it achieved revenue of 624 million yuan, an increase of 92.07% year on year; the net profit attributable to shareholders of listed companies was 181 million yuan, an increase of 84.37% year on year In addition, it is estimated that the net profit attributable to shareholders of the listed company in the quarter of 2019 will be 62.2056 million yuan to 69.9813 million yuan, up 100% - 125% year on year As for the reasons for the improvement in the first quarter of 2019, the company said that the main reason is that in the first quarter of 2019, the company continued to strengthen the development and management of international and domestic markets, and its first quarter operating revenue grew steadily compared with the same period last year It is estimated that the impact of non recurring profit and loss on net profit during the reporting period is about 400000 yuan, with little impact The net profit of HongRi pharmaceutical in 2018 decreased by 53.23%, and the annual report of HongRi pharmaceutical in 2018 was issued recently, realizing the operating revenue of 4.224 billion yuan, an increase of 25.19% year on year; the operating profit of 292 million yuan, a decrease of 44.49% year on year; the total profit of 324 million yuan, a decrease of 43.68% year on year; the net profit attributable to shareholders of listed companies was 211 million yuan, a decrease of 53.23% year on year The company said that the decrease in profit was mainly due to the impairment of goodwill of its subsidiary, Chaosi electronics and prospect pharmaceutical In 2018, the net profit of Yifan pharmaceutical decreased by 44% year on year Recently, Yifan pharmaceutical released the financial report of 2018, which showed that in the reporting period, the revenue was 4.632 billion yuan, an increase of 5.91% year on year; the net profit attributable to shareholders of listed companies was 737 million yuan, a decrease of 43.50% year on year   According to the report, in 2018, the main performance drivers are: in the company's API sector, the market price of vitamin B5 products fell from a high level, but the company continued to maintain its market position and market share by taking advantage of its product technology and cost advantages; at the same time, by taking advantage of the rising price of vitamin B5 products, the company increased the sales of vitamin B5 products, making vitamin B5 products The operating performance showed a multiple growth, reducing the decline in the revenue and profit of API sector during the reporting period   During the reporting period, in the pharmaceutical preparation sector, the company made use of its own resource advantages in academic promotion and marketing network to continuously expand the market, so that the performance of cooperative (Agency) products was still growing steadily; at the same time, on the basis of early internal enterprise, business and product integration, the company increased the market development and promotion of other self owned products, so that the self owned products grew during the reporting period Obviously, they all lay the foundation for the realization of the company's overall performance On April 1, 2018, the net profit of Haichen Pharmaceutical Co., Ltd increased by 26.86% year on year According to the 2018 annual report issued by Haichen Pharmaceutical Co., Ltd., the total operating revenue of the company was 712 million yuan, an increase of 56.45% year on year, and the net profit was 83 million yuan, an increase of 26.86% year on year According to the public information, Haichen pharmaceutical mainly engages in the research and development, production and marketing of chemical drugs, which is classified as "C27 pharmaceutical manufacturing industry" in the industry classification of listed companies of CSRC.